221 related articles for article (PubMed ID: 24974886)
1. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients.
Li Y; Shi Y; Liao Y; Yan L; Zhang Q; Wang L
Int Immunopharmacol; 2015 Sep; 28(1):435-43. PubMed ID: 26186486
[TBL] [Abstract][Full Text] [Related]
4. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
5. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
7. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
Levitsky J; Mathew JM; Abecassis M; Tambur A; Leventhal J; Chandrasekaran D; Herrera N; Al-Saden P; Gallon L; Abdul-Nabi A; Yang GY; Kurian SM; Salomon DR; Miller J
Hepatology; 2013 Jan; 57(1):239-48. PubMed ID: 22234876
[TBL] [Abstract][Full Text] [Related]
8. mTOR Signaling pathway as a master regulator of memory CD8
Rostamzadeh D; Yousefi M; Haghshenas MR; Ahmadi M; Dolati S; Babaloo Z
J Cell Physiol; 2019 Aug; 234(8):12353-12368. PubMed ID: 30710341
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study.
Santos AH; Chen C; Alquadan K; Wen X
Int Urol Nephrol; 2019 Nov; 51(11):2063-2072. PubMed ID: 31385180
[TBL] [Abstract][Full Text] [Related]
10. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression.
Chung BH; Kim BM; Doh KC; Min JW; Cho ML; Kim KW; Yang CW
Transplantation; 2017 Jul; 101(7):1711-1719. PubMed ID: 28107277
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of T Helper Cell Differentiation by Tacrolimus or Sirolimus Results in Reduced B-Cell Activation: Effects on T Follicular Helper Cells.
Kraaijeveld R; Li Y; Yan L; de Leur K; Dieterich M; Peeters AMA; Wang L; Shi Y; Baan CC
Transplant Proc; 2019 Dec; 51(10):3463-3473. PubMed ID: 31733794
[TBL] [Abstract][Full Text] [Related]
12. Th1, Th2, Th17 cell subsets in two different immunosuppressive protocols in renal allograft recipients (Sirolimus vs mycophenolate mofetil): A cohort study.
Eteghadi A; Pak F; Ahmadpoor P; Jamali S; Karimi M; Yekaninejad MS; Kokhaei P; Nafar M; Amirzargar AA
Int Immunopharmacol; 2019 Feb; 67():319-325. PubMed ID: 30576916
[TBL] [Abstract][Full Text] [Related]
13. Effects of resveratrol on Th17 cell-related immune responses under tacrolimus-based immunosuppression.
Doh KC; Kim BM; Kim KW; Chung BH; Yang CW
BMC Complement Altern Med; 2019 Mar; 19(1):54. PubMed ID: 30832648
[TBL] [Abstract][Full Text] [Related]
14. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
Levitsky J; Gallon L; Miller J; Tambur AR; Leventhal J; Flaa C; Huang X; Sarraj B; Wang E; Mathew JM
Transplantation; 2011 Jan; 91(2):199-206. PubMed ID: 21239962
[TBL] [Abstract][Full Text] [Related]
15. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
[TBL] [Abstract][Full Text] [Related]
16. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
17. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carroll RP; Hester J; Wood KJ; Harden PN
Nephrol Dial Transplant; 2013 Feb; 28(2):462-5. PubMed ID: 23223314
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
19. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
20. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
